Zhaoqing

Researchers are evaluating combined screening methods for gastrointestinal tumors to explore their feasibility and health economic benefits. This population-based, multicenter cohort study focuses on screening for esophagus, stomach, and colorectal cancer in adults aged 45 to 70 years. The study aims to establish effective gastroenteroscopy screening and follow-up management over a 10-year period to detect cancer or precancerous lesions. Participants are divided into groups receiving different screening interventions. Group one undergoes gastroscopy, colonoscopy, fecal occult blood test (FIT), Helicobacter pylori antigen test, RNF180 and SEPTIN9 gene methylation tests, along with an investigation of various risk factors such as medical history, lifestyle habits, and family cancer history. Group two receives risk factor investigation, FIT, and stool Helicobacter pylori antigen testing, with follow-up gene methylation testing and colonoscopy if initial tests are positive. Control groups consist of spouses or siblings of the screening groups, who only participate in risk factor investigation. Throughout the study, participants will be monitored for up to 10 years to observe the development of cancer or precancerous lesions. Assessments include various tests, questionnaires about lifestyle and medical history, and follow-up visits. Researchers will measure outcomes related to cancer detection and evaluate the overall impact and benefits of the combined screening approach compared to control groups, ensuring safety and adherence to protocols.

This research aims to describe the clinical characteristics, treatment patterns, and biomarkers of asthma patients in the Chinese population. It seeks to identify different phenotypes and endotypes related to varying outcomes, which could help develop personalized treatment strategies for asthma in the future. The study focuses on adults aged 18 to 75 years with physician-diagnosed asthma lasting at least three months before screening. Participants will undergo baseline assessments including lung function tests such as FEV1, Forced Vital Capacity (FVC), and Maximal Mid Expiratory Flow (MMEF). Imaging studies like Computed Tomography (CT) scans will evaluate airway remodeling and gas trapping. Biomarker levels will also be collected to support statistical clustering and analysis of asthma subtypes. During the study, researchers will summarize demographic, clinical, and functional data alongside biomarker findings at baseline. These comprehensive evaluations aim to better understand asthma characteristics and support future personalized treatment development. The total participation duration and further study procedures beyond baseline assessments are not specified.

People with end stage kidney disease (ESKD) who require dialysis have a much higher risk of developing cardiovascular disease compared to the general population, with heart problems causing over half of the deaths in this group. This trial is studying whether taking low dose aspirin daily can safely reduce cardiovascular events in these dialysis patients. The study is a Phase 4, multi-center, randomized controlled trial designed to provide clear evidence about aspirin's benefits and risks in this specific population, where existing data is limited. Participants will be randomly assigned to receive either a daily 100 mg aspirin tablet or a matching placebo. The trial uses the Chinese peritoneal dialysis and hemodialysis registry to efficiently screen and recruit patients and collect data during routine dialysis care. Follow-up visits occur every six months as part of regular clinical care, and the study will continue until enough cardiovascular events have occurred, expected to take about five years. During the study, participants will have their health monitored through routine clinic visits every six months, with data collected on cardiovascular events and safety. The main outcome measured is the number of participants experiencing major cardiovascular events over the study period. An independent board will oversee safety and study progress. The trial uses intention-to-treat analysis and aims to minimize participant burden by integrating study procedures into usual care.

Researchers are evaluating the effect of absorbable and moldable skull base support plates in patients with sellar region tumors undergoing extended endoscopic endonasal transsphenoidal surgery. This phase II, multicenter, randomized, controlled trial aims to compare the incidence of cerebrospinal fluid (CSF) rhinorrhea within 1 month after surgery between the group receiving standard sellar floor repair combined with the support plates and the group receiving only standard sellar floor repair. The study also assesses secondary outcomes including intracranial infection rates, surgery duration, hospital stay length, and safety, particularly nasal complications. Participants will be randomly assigned to one of two groups: one group will have the standard sellar floor repair plus the absorbable and moldable skull base support plate used during the skull base repair phase, while the other group will receive standard sellar floor repair alone. The support plate is trimmed and shaped to fit the skull base defect and positioned securely under bone edges to prevent gaps. Approximately 126 participants, aged 1 to 80 years, will be enrolled with a 1:1 allocation to each group. During the study, participants will be monitored for signs of CSF rhinorrhea and intracranial infection within 1 month following surgery through clinical symptoms, imaging, and nasal endoscopy. Surgery duration and hospital stays will be recorded. Safety assessments will include monitoring for adverse events and nasal complications. Follow-up will be conducted face-to-face or by telephone for those unable to return for reexamination. Statistical analysis will be performed to compare outcomes between groups with significance set at P < 0.05.

Researchers are studying how changes in circulating multigene methylation levels relate to treatment responses in people with esophageal cancer. The goal is to see if these methylation changes correlate with objective response rates measured by contrast-enhanced CT or MRI scans and serum tumor markers. The study also aims to explore the relationship between methylation patterns and progression-free survival, compare methylation indices with traditional biomarkers, and assess if methylation thresholds can guide changes in therapy. Participants will undergo multi-gene methylation testing through blood samples during follow-up visits. There are four groups based on treatment types and timing: preoperative, pre-neoadjuvant therapy, post-neoadjuvant therapy, and pre- and post-definitive chemoradiotherapy. Each group will have scheduled methylation testing at multiple time points from baseline up to five years after treatment. During the study, participants will have blood tests to measure methylation levels at various intervals, along with imaging scans and serum marker evaluations to monitor treatment response. Researchers will track methylation changes over time and relate them to clinical outcomes like progression-free survival. The follow-up lasts up to five years, allowing close observation of long-term treatment effects and disease status.

Researchers are evaluating the effectiveness and safety of a chemotherapy drug called JSKN003 compared to other chemotherapy treatments chosen by doctors for adults with HER2-low, unresectable, or metastatic breast cancer. This study focuses on patients whose cancer has returned or spread and who have already tried one or two previous chemotherapy treatments without success. It is a phase III, open-label, randomized study conducted at multiple centers. Participants will be randomly assigned to one of two groups: one group will receive JSKN003 given through an intravenous infusion according to the study plan, while the other group will receive one of several chemotherapy drugs selected by their doctor before joining the study. These options include capecitabine, gemcitabine, vinorelbine, docetaxel, albumin-bound paclitaxel, or eribulin. Treatment is given as a single drug in both groups. During the study, participants will be monitored for up to about three years to see how long they live without their cancer worsening. Researchers will conduct imaging scans, lab tests, and other evaluations to track disease progression and overall health. Safety and side effects will be carefully observed, and participants' tumor samples will be analyzed to confirm HER2 status. The study aims to enroll 408 subjects and includes follow-up assessments to ensure continued monitoring of treatment outcomes.

Researchers are evaluating the safety and effectiveness of orelabrutinib combined with the R-CHOP chemotherapy regimen as a first treatment for patients with CD5-positive diffuse large B-cell lymphoma (DLBCL). This phase II clinical trial involves patients with untreated CD5-positive DLBCL to better understand how this combination therapy works and how safe it is for patients. The treatment includes six cycles of R-CHOP chemotherapy, with orelabrutinib added starting from the second cycle. After these six cycles, patients receive two additional cycles of rituximab plus orelabrutinib, completing a total of eight treatment cycles. Patients who achieve complete remission after these eight cycles may then continue with maintenance therapy using orelabrutinib. Participants will be closely monitored throughout the study, with researchers measuring the primary outcome of event-free survival over two years. This means tracking the proportion of patients who do not experience disease progression, stop treatment, or die for any reason within 24 months after enrollment. Safety and treatment response will also be assessed during the study period.

Researchers are investigating the effects of thrombus aspiration (TA) in patients experiencing ST-segment Elevation Myocardial Infarction (STEMI) who have a high thrombus burden, indicated by a TIMI thrombus grade of 3 or higher. This prospective, multicenter, open-label, randomized controlled trial aims to compare outcomes between patients treated with or without manual thrombus aspiration during primary percutaneous coronary intervention (PPCI) performed within 12 hours of symptom onset. The goal is to assess if TA reduces major cardiovascular events including cardiovascular death, recurrent heart attacks, stent thrombosis, target vessel revascularization within 180 days, or stroke within 30 days. Participants are randomly assigned in a 1:1 ratio to receive either primary PCI with manual thrombus aspiration or PCI alone without thrombus aspiration. Both procedures are performed as part of the treatment for STEMI patients with high thrombus burden. The study evaluates the safety and efficacy of adding thrombus aspiration to the standard PCI process. During the study, patients will be monitored for up to 180 days to track the occurrence of major adverse cardiovascular events. Researchers will collect data on cardiovascular death, recurrent myocardial infarction, stent thrombosis, need for target vessel revascularization, and stroke. Follow-up evaluations will help determine the overall impact of thrombus aspiration on patient outcomes after STEMI treatment.